Skip Navigation


Annals of Oncology Advance Access originally published online on January 10, 2005
Annals of Oncology 2005 16(3):359-371; doi:10.1093/annonc/mdi090
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
16/3/359    most recent
mdi090v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (23)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Menendez, J. A.
Right arrow Articles by Lupu, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Menendez, J. A.
Right arrow Articles by Lupu, R.
Related Collections
Right arrow 2005 - Editors Choice
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2005 European Society for Medical Oncology

Oleic acid, the main monounsaturated fatty acid of olive oil, suppresses Her-2/neu (erbB-2) expression and synergistically enhances the growth inhibitory effects of trastuzumab (HerceptinTM) in breast cancer cells with Her-2/neu oncogene amplification

J. A. Menendez1,2,*, L. Vellon1, R. Colomer3 and R. Lupu1,2,*

1 Department of Medicine, Breast Cancer Translational Research Laboratory, Evanston Northwestern Healthcare Research Institute, Evanston, IL; 2 Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, USA; 3 Institut Catala d'Oncologia, Hospital Universitari de Girona Dr Josep Trueta, Girona, Spain

* Correspondence to: Dr J. A. Menendez or Ruth Lupu, Evanston Northwestern Healthcare Research Institute, 1001 University Place, Evanston, IL 60201, USA. Tel: +1-847-570-7672; Fax: +1-847-570-8022; Email: jmenendez{at}enh.org orEmail: r-lupu{at}northwestern.edu

Background: The relationship between the intake of olive oil, the richest dietary source of the monounsaturated fatty acid oleic acid (OA; 18:1n-9), and breast cancer risk and progression has become a controversial issue. Moreover, it has been suggested that the protective effects of olive oil against breast cancer may be due to some other components of the oil rather than to a direct effect of OA.

Methods: Using flow cytometry, western blotting, immunofluorescence microscopy, metabolic status (MTT), soft-agar colony formation, enzymatic in situ labeling of apoptosis-induced DNA double-strand breaks (TUNEL assay analyses), and caspase-3-dependent poly-ADP ribose polymerase (PARP) cleavage assays, we characterized the effects of exogenous supplementation with OA on the expression of Her-2/neu oncogene, which plays an active role in breast cancer etiology and progression. In addition, we investigated the effects of OA on the efficacy of trastuzumab (HerceptinTM), a humanized monoclonal antibody binding with high affinity to the ectodomain of the Her-2/neu-coded p185Her-2/neu oncoprotein. To study these issues we used BT-474 and SKBr-3 breast cancer cells, which naturally exhibit amplification of the Her-2/neu oncogene.

Results: Flow cytometric analyses demonstrated a dramatic (up to 46%) reduction of cell surface-associated p185Her-2/neu following treatment of the Her-2/neu-overexpressors BT-474 and SK-Br3 with OA. Indeed, this effect was comparable to that found following exposure to optimal concentrations of trastuzumab (up to 48% reduction with 20 µg/ml trastuzumab). Remarkably, the concurrent exposure to OA and suboptimal concentrations of trastuzumab (5 µg/ml) synergistically down-regulated Her-2/neu expression, as determined by flow cytometry (up to 70% reduction), immunoblotting, and immunofluorescence microscopy studies. The nature of the cytotoxic interaction between OA and trastuzumab revealed a strong synergism, as assessed by MTT-based cell viability and anchorage-independent soft-agar colony formation assays. Moreover, OA co-exposure synergistically enhanced trastuzumab efficacy towards Her-2/neu overexpressors by promoting DNA fragmentation associated with apoptotic cell death, as confirmed by TUNEL and caspase-3-dependent PARP cleavage. In addition, treatment with OA and trastuzumab dramatically increased both the expression and the nuclear accumulation of p27Kip1, a cyclin-dependent kinase inhibitor playing a key role in the onset and progression of Her-2/neu-related breast cancer. Finally, OA co-exposure significantly enhanced the ability of trastuzumab to inhibit signaling pathways downstream of Her-2/neu, including phosphoproteins such as AKT and MAPK.

Conclusions: These findings demonstrate that OA, the main monounsaturated fatty acid of olive oil, suppresses Her-2/neu overexpression, which, in turn, interacts synergistically with anti-Her-2/neu immunotherapy by promoting apoptotic cell death of breast cancer cells with Her-2/neu oncogene amplification. This previously unrecognized property of OA offers a novel molecular mechanism by which individual fatty acids may regulate the malignant behavior of breast cancer cells and therefore be helpful in the design of future epidemiological studies and, eventually, dietary counseling.

Key words: apoptosis, breast cancer, fatty acids, Her-2/neu, oleic acid, trastuzumab


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Professional Animal ScientistHome page
P. Gregorini, K. J. Soder, and M. A. Sanderson
Case Study: A Snapshot in Time of Fatty Acids Composition of Grass Herbage as Affected by Time of Day
Professional Animal Scientist, December 1, 2008; 24(6): 675 - 680.
[Abstract] [PDF]

Home page
 Endocr. Rev.Home page
M. Prentki and S. R. M. Madiraju
Glycerolipid Metabolism and Signaling in Health and Disease
Endocr. Rev., October 1, 2008; 29(6): 647 - 676.
[Abstract] [Full Text] [PDF]

Home page
 J. Nutr.Home page
S. Lopez, B. Bermudez, Y. M. Pacheco, G. Lopez-Lluch, W. Moreda, J. Villar, R. Abia, and F. J. G. Muriana
Dietary Oleic and Palmitic Acids Modulate the Ratio of Triacylglycerols to Cholesterol in Postprandial Triacylglycerol-Rich Lipoproteins in Men and Cell Viability and Cycling in Human Monocytes
J. Nutr., September 1, 2007; 137(9): 1999 - 2005.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
A. C. Chandra-Shekara, S. C. Venugopal, S. R. Barman, A. Kachroo, and P. Kachroo
Plastidial fatty acid levels regulate resistance gene-dependent defense signaling in Arabidopsis
PNAS, April 24, 2007; 104(17): 7277 - 7282.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
D. J. Kerr
KISS: the 2006 Annals of Oncology prizes
Ann. Onc., September 1, 2006; 17(9): 1341 - 1342.
[Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
J. A. Menendez and R. Lupu
RESPONSE: Re: Effect of {gamma}-Linolenic Acid on the Transcriptional Activity of the Her-2/neu (erbB-2) Oncogene
J Natl Cancer Inst, May 17, 2006; 98(10): 718 - 720.
[Full Text] [PDF]

Home page
 Integr Cancer TherHome page
D. R. Yance Jr and S. M. Sagar
Targeting Angiogenesis With Integrative Cancer Therapies
Integr Cancer Ther, March 1, 2006; 5(1): 9 - 29.
[Abstract] [PDF]

Home page
 BMJHome page
In brief
BMJ, January 15, 2005; 330(7483): 110 - 110.
[Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.